Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

被引：0
|
作者：
Shigeki Nanjo
Akito Hata
Chiyuki Okuda
Reiko Kaji
Hideaki Okada
Daisuke Tamura
Kei Irie
Hiroshi Okada
Shoji Fukushima
Nobuyuki Katakami
机构：
[1] Institute of Biomedical Research and Innovation Hospital,Division of Integrated Oncology
[2] 2-2,Department of Medical Oncology
[3] Minatojima-minamimachi,Department of Respiratory Medicine
[4] Chuo-ku,Department of Pharmacology
[5] Kobe 650-0047,Department of Pharmaceutics
[6] Japan,undefined
[7] Kobe Minimally Invasive Cancer Center,undefined
[8] Kobe 650-0046,undefined
[9] Japan,undefined
[10] Kobe University Hospital,undefined
[11] Kobe 650-0017,undefined
[12] Japan,undefined
[13] Institute of Biomedical Research and Innovation Hospital,undefined
[14] Kobe 650-0047,undefined
[15] Japan,undefined
[16] Faculty of Pharmaceutical Science,undefined
[17] Kobe Gakuin University,undefined
[18] Kobe 650-8586,undefined
[19] Japan,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
osimertinib; leptomeningeal metastases; T790M; cerebrospinal fluid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：32 / 37
页数：5
相关论文
共 50 条
  • [31] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [32] Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Eide, Inger Johanne Zwicky
    Helland, Aslaug
    Ekman, Simon
    Mellemgaard, Anders
    Hansen, Karin Holmskov
    Cicenas, Saulius
    Koivunen, Jussi
    Gronberg, Bjorn Henning
    Brustugun, Odd Terje
    LUNG CANCER, 2020, 143 : 27 - 35
  • [33] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
    Mok, T. S.
    Wu, Y. -L.
    Ahn, M. -J.
    Garassino, M. C.
    Kim, H. R.
    Ramalingam, S. S.
    Shepherd, F. A.
    He, Y.
    Akamatsu, H.
    Theelen, W. S. M. E.
    Lee, C. K.
    Sebastian, M.
    Templeton, A.
    Mann, H.
    Marotti, M.
    Ghiorghiu, S.
    Papadimitrakopoulou, V. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07): : 629 - 640
  • [34] Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer
    Martinez Vila, Clara
    Garcia Garcia, Yolanda
    Carcereny Costa, Enric
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : E77 - E79
  • [35] Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis
    Wang, Chunsheng
    Zhao, Kewei
    Hu, Shanliang
    Li, Minghuan
    Song, Yipeng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment
    Su, Po-Lan
    Tsai, Jeng-Shiuan
    Yang, Szu-Chun
    Wu, Yi-Lin
    Tseng, Yau-Lin
    Chang, Chao-Chun
    Yen, Yi-Ting
    Lin, Chia-Ying
    Lin, Chien-Chung
    Wang, Chin-Chou
    Lin, Meng-Chih
    Su, Wu-Chou
    LUNG CANCER, 2021, 158 : 137 - 145
  • [37] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [38] CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
    Paz-Ares, L.
    Planchard, D.
    Yang, J. C.
    Lee, K.
    Garrido, P.
    Park, K. K.
    Kim, J.
    Lee, D. H.
    Mao, H.
    Chao, B.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S454
  • [39] ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
    Kejun Liu
    Xianwen Chen
    Ligang Wu
    Shiyuan Chen
    Nianxin Fang
    Limin Cai
    Jun Jia
    BMC Pulmonary Medicine, 21
  • [40] Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
    Kazmierczak, Dominika
    Eide, Inger Johanne Zwicky
    Gencheva, Radosveta
    Lai, Yi
    Lewensohn, Rolf
    Tsakonas, Georgios
    Grundberg, Oscar
    de Petris, Luigi
    McGowan, Marc
    Brustugun, Odd Terje
    Ekman, Simon
    Hydbring, Per
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 722 - +
12345